Advertisement

Banner Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Collaboration › Details

Sanofi–Organobalance: yeast technology, 201201– license excl for vaccine production of modified S. cerevisiae strain to Sanofi Pasteur

 

Period Period 2012-01-11
Organisations Partner, 1st Sanofi Pasteur (Group)
  Group Sanofi (Group) [since May 2011]
  Partner, 2nd Organobalance GmbH
Products Product recombinant protein production in yeast cells
  Product 2 vaccine
     

Organobalance GmbH. (1/11/12). "Press Release: Organobalance Signs Licensing Agreement with Sanofi Pasteur. Modified Strain of Yeast Paves Way for New Industrial Vaccine Production Process". Berlin.

The company ORGANOBALANCE GmbH, Berlin, Germany, today announced the conclusion of a licensing agreement with Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY). This will provide Sanofi Pasteur with access to a modified yeast strain (Saccharomyces cerevisiae, more commonly known as baker's yeast) for use in vaccines. By signing the agreement, ORGANOBALANCE is granting Sanofi Pasteur exclusive rights to use of the modified yeast strain in the production of vaccines.

Prof. Christine Lang, Managing Director of ORGANOBALANCE GmbH, sees the licensing agreement as a further milestone for the company: "The modified form of Saccharomyces cerevisiae, both developed and patented by our company, is just one example of the farreaching expertise ORGANOBALANCE has to offer in the field of metabolic engineering. By making this agreement, we are strengthening our outstanding position in microbial strain development and the application of yeasts in industrial biotechnology. We are delighted to have made this agreement with Sanofi Pasteur, a partner who will make commercial use of our research findings on an industrial scale."


About ORGANOBALANCE:

ORGANOBALANCE GmbH is a company specialising in microbiological strain development. ORGANOBALANCE targets the use of Saccharomyces cerevisiae yeast strains for synthesising materials which can be applied in the processes of industrial and pharmaceutical biotechnology. The company also focuses on tapping the potential of beneficial microorganisms, known as specific probiotic cultures, in order to balance out the microflora and restore the microbial equilibrium in a natural way. By drawing on its own collection of microorganisms suitable for use in foodstuffs, as well as its own OASSYS® screening systems, ORGANOBALANCE develops new biological products in the areas of pharmaceutics, preventive healthcare, nutrition and cosmetics. ORGANOBALANCE was founded in 2001 and is based in Berlin, Germany. More information can be found at http://www.organobalance.com.


Further information:

ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin
Germany
Tel.: +49 30 46307-200
Fax: +49 30 46307-210
Email: info@organobalance.com
Internet: http://www.organobalance.com

Press contact:

COMAGO
Communication . Marketing . Organisation
Helmut Landenberger
Wiesenstraße 55
14612 Falkensee
Germany
Tel.: +49 33 22 84 06 52
Fax: +49 33 22 84 06 53
Email: mail@comago.de
Internet: http://www.comago.de

   
Record changed: 2012-02-05

Advertisement

Banner LSBC Central European Life Science Investment Conference 2014 600x60px

More documents for Sanofi (Group) [since May 2011]


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Erfolgreicher Nischenanbieter im LC/MS-Markt sucht Junior-Partner 600x60px




» top

Advertisements

Banner EBD Group BIO Europe 2013 BEU Frankfurt November 120x120px Highl Successful LC/MS Niche Player Is Looking for a Junior Partner 120x240px The Events Group Pharm Connect Congress 2015 Budapest February 120x180px Banner C5 Communications Life Sciences IP Summit 2014 Amsterdam 120x180px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Banner [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px